Melphalan liver perfusion followed by tebentafusp for metastatic uveal melanoma

Phase 2 Sequential Treatment With Melphalan/HDS Via Percutaneous Hepatic Perfusion Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma

This Phase 2 trial tests whether melphalan delivered to the liver by percutaneous hepatic perfusion followed by tebentafusp helps people with HLA-A*02:01-positive metastatic uveal melanoma confined to the liver.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: H. Lee Moffitt Cancer Center and Research Institute (Academic / other)
• Drugs / interventions: radiation, prednisone
• Locations: 1 site (Tampa, Florida)
• Trial ID: NCT07276386 on ClinicalTrials.gov

What this trial studies

This Phase 2 interventional study gives percutaneous hepatic perfusion (PHP) with melphalan/HDS to patients with isolated liver metastases from uveal melanoma, followed by systemic tebentafusp for those who are HLA-A*02:01-positive. The approach aims to use regional high-dose chemotherapy to increase antigen release and modify the tumor microenvironment so tebentafusp's T-cell–redirecting activity can be more effective. Eligible adults must have ECOG 0–1, measurable liver disease by RECIST 1.1, and be suitable for both PHP and tebentafusp. The trial is conducted at H. Lee Moffitt Cancer Center and will track tumor response in the liver, survival outcomes, and safety signals.

Who should consider this trial

Good fit: Adults (≥18) with ECOG 0–1, HLA-A*02:01-positive uveal melanoma with measurable, liver-only metastases who are medically fit for percutaneous hepatic perfusion and tebentafusp are the intended candidates.

Not a fit: Patients who are not HLA-A*02:01-positive, have widespread extrahepatic disease, poor performance status (ECOG >1), or cannot undergo hepatic perfusion are unlikely to benefit from this approach.

Why it matters

Potential benefit: If successful, the combination could improve liver tumor control and extend progression-free and overall survival for HLA-A*02:01-positive patients with liver-only metastatic uveal melanoma.

How similar studies have performed: Tebentafusp has shown a survival benefit in HLA-A*02:01-positive metastatic uveal melanoma and PHP has produced meaningful liver responses in prior reports, but the sequential combination is novel and not yet proven.

Eligibility criteria

Inclusion Criteria:

* Patient is ≥18 years of age on the day of signing informed consent.
* ECOG performance status of 0 or 1.
* Histologically or cytologically confirmed liver metastasis of uveal melanoma.
* HLA-A\*02:01 positive status.
* Measurable disease by computed tomography (CT) per RECIST 1.1 with at least one target lesion identified in the liver.
* Patient deemed suitable for PHP and tebentafusp.
* Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
* Female patients of childbearing potential must be willing to use an adequate method of contraception, for the course of the study through 150 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
* Male patients of childbearing potential must agree to use an adequate method of contraception, starting with the first dose of study therapy through 150 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
* Limited extrahepatic disease would be allowed initially, that can be treated with stereotactic body radiation therapy (SBRT) or surgical resection prior to the start of tebentafusp. This concept is similar to the FOCUS trial - definition of "treatable" limited disease at the discretion of the PI.
* Ability to provide and understand written informed consent prior to any study procedures.

Exclusion Criteria:

* Life expectancy of less than 6 months.
* More than 50% of the liver volume replaced by tumor as measured by MRI.
* Extrahepatic disease as measured by CT of thorax abdomen and pelvis. (See inclusion criteria #10 above for limited treatable extrahepatic disease.)
* History of congestive heart failure, active cardiac conditions, including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), significant arrhythmias and severe valvular disease that precludes the use of general anesthesia.
* History or evidence of clinically significant pulmonary disease e.g. severe COPD that precludes the use of general anesthesia.
* Patients who are unable to undergo general anesthesia for any reason.
* Reduced renal function defined as Serum Creatinine \>=1.5xULN or Creatinine Clearance \< 40 mL/min, calculated using the Cockcroft and Gault formula.
* Reduced hepatic function (defined as AST, ALT, bilirubin\>2.5\*ULN and PT-INR\>1.5) or medical history of liver cirrhosis (Child-Pugh Class B or C) or evidence of portal hypertension by history, endoscopy or radiology.
* Hemoglobin \<90 g/L or platelets \<100x109/L or neutrophils \<1.5x109/L.
* Use of live vaccines four weeks before the last study treatment.
* History of severe reactions to melphalan, heparin or iodine contrast. Iodine contrast reaction history patients permitted if patient will be treated with pre-meds, or if still problematic, treating physician may switch to MRI TAP.
* Known human immunodeficiency virus (HIV) infection, acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C.
* Active autoimmune disease or a documented history of autoimmune disease requiring active systemic immunosuppressive treatment. Type-1 diabetes, atopic dermatitis, and hypothyroidism are exceptions to this.
* A condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \>10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
* Concomitant therapy with any other anti-cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications (other than physiologic (i.e., \>10 mg) doses of steroids or as specified in exclusion #14) or use of other investigational drugs.
* Has a known additional malignancy that is progressing or requires active treatment.
* Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 150 days after the last dose of study drug.
* A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate in the opinion of the treating investigator.
* Previous treatment with PHP or tebentafusp.

Where this trial is running

Tampa, Florida

• Moffitt Cancer Center — Tampa, Florida, United States (Recruiting)

Study contacts

• Principal investigator: Jonathan Zager, MD, FACS — Moffitt Cancer Center
• Study coordinator: Deanryan De Aquino

Conditions Metastatic Uveal Melanoma